RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

Clinical trial NCT07732634 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07732634
Sponsor: University of Illinois at Chicago
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Cancer Head Cancer Neck Cancer

Start date: 2026-08-01
Primary completion: 2029-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.